Compare Duke Energy Corp (DUK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Summit Therapeutics Inc — how do they compare? Duke Energy Corp trades at $126.12 (market cap $98.52B), while Summit Therapeutics Inc trades at $15.37 (market cap $12.01B). The key difference: Duke Energy Corp is far larger — about 8.2× Summit Therapeutics Inc's market cap, and Duke Energy Corp pays a 3.37% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DUK | SMMT | |
|---|---|---|
Market Cap | $98.52B | $12.01B |
Sector | Utilities | Health |
52-Week High | $133.46 | $29.32 |
52-Week Low | $113.99 | $13.05 |
Enterprise Value | $188.56B | $11.43B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $126.86, up 1.1% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows stable revenue growth, with 2025 revenue reaching $32.24B and net income of $4.97B, supported by a 15.49% net margin. Recent news highlights a dividend increase to $1.085 per share and strong institutional interest, with 37.5% of analysts rating it a Buy.
The outlook remains positive with a consensus price target of $136.60, offering ~7.7% upside. Risks include high debt levels (46.17% debt-to-asset ratio) and regulatory pressures, but the company's defensive utility profile and dividend reliability provide stability amid market volatility.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
